The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 82K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pique, C.
Right arrow Articles by Dokhélar, M.-C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pique, C.
Right arrow Articles by Dokhélar, M.-C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/2000/2/567/ $5.00
The Journal of Experimental Medicine, Volume 191, Number 3, February 7, 2000 567-572

Brief Definitive Report

Evidence for the Chronic in Vivo Production of Human T Cell Leukemia Virus Type I Rof and Tof Proteins from Cytotoxic T Lymphocytes Directed against Viral Peptides

Claudine Piquea,b, Abel Ureta-Vidald, Antoine Gessaine, Bruno Chancerelf, Olivier Goutg, Riad Tamouzac, Frantz Agisf, and Marie-Christine Dokhélara

a Institut National de la Santé et de la Recherche Médicale, U332, Institut Cochin de Génétique Moléculaire, 75014 Paris, France
b Centre National de la Recherche Scientifique, UPR 9051,
c Laboratoire d'Immunologie et d'Histocompatibilité, Hôpital St. Louis, 75010 Paris, France
d Unité d'Immunité Cellulaire Antivirale, Institut Pasteur, 75015 Paris, France
e Unité d'Oncologie Virale, Institut Pasteur, 75015 Paris, France
f Etablissement de Transfusion Sanguine, Guadeloupe, 97171 Pointe-à-Pitre, Guadeloupe
g Fédération de Neurologie, Hôpital de la Pitié-Salpétrière, 75013 Paris, France
CNRS UPR 9051, Hôpital St. Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France.33-1-53-72-40-9033-1-53-72-40-95

pique{at}chu-stlouis.fr

Human T cell leukemia virus type I (HTLV-I) is a persistent virus that causes adult T cell leukemia and tropical spastic paraparesis/HTLV-I–associated myelopathy. Studies on rabbits have shown that viral proteins encoded by the open reading frames pX-I and pX-II are required for the establishment of the persistent infection. To examine the in vivo production of these proteins in humans, we have investigated whether cytotoxic T lymphocytes isolated from HTLV-I–infected individuals recognized pX-I and pX-II peptides. CD8+ T lymphocytes to pX-I and pX-II peptides were detected in HTLV-I–infected individuals, whatever their clinical status, and even in the absence of any antigenic restimulation. These findings indicate that the HTLV-I pX-I and pX-II proteins are chronically synthesized in vivo, and are targets of the natural immune response to the virus.

Key Words: retrovirus • regulatory proteins • cytotoxic epitopes • HLA-A2 • interferon {gamma}

© 2000 The Rockefeller University Press


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS